Sanofi (SNY)

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

• 6d agoPOSITIVE
  Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

  Sanofi has announced the discontinuation of its Phase 3 riliprubart study for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) due to insufficient efficacy. This setback for Sanofi's drug development pipeline may inadvertently strengthen the market position of Argenx's Vyvgart, a competing treatment for CIDP. While Sanofi's stock saw a slight uptick, potentially reflecting relief from the costs associated with the failed trial, the news highlights a competitive advantage for Argenx in the CIDP therapeutic area. Investors will monitor Argenx's progress and market penetration strategies.